Study bolsters hopes for prostate cancer vaccine rejected by FDA

The vaccine, Provenge, extended life an average of four months, nearly twice as long as the best available chemotherapy, researchers say. A controversial prostate cancer vaccine that previously had been rejected by the Food and Drug Administration improves survival of patients with the advanced form of the disease more than existing treatments and should be brought to market, researchers said Tuesday.

Read the whole article on LA Times - Science

More from LA Times - Science